Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available
Subjects with life expectancy of 12 weeks or longer.
Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
You may not be if
Subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-C or nitrosoureas.
Subjects with history of brain metastases or spinal cord compression.
Subjects who have undergone a bone marrow or solid organ transplant.
Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment.
Subjects with a history of any gastrointestinal condition
Is receiving any compound that is known to be a potent inducer or inhibitor of CYP3A4
Subjects with an active autoimmune process or is receiving therapy for an autoimmune disease
Subjects treated with a serotonin reuptake inhibitor within 3 weeks prior to study entry
Clareo Health | A Dose-escalation Study in Subjects With Advanced Malignancies
